NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Why would the vaccine for crossovers when based on the original tumor and not the recurrent (or progressing) tumor put crossovers at a disadvantage?

Mutation and loss of original antigen profile, movement toward mesenchymal with different antigen makeup.

Would it not be a disadvantage for trial as well?

Yes, hence why I see less chance for big crossover impact in the phase III trial (unless there was midstream optimization)

As I see it the main advantage the trial patients have over crossovers is the added initial protection they receive before they progress. Maybe I am wrong but it seems to me that is why a survival difference between trial and control prior to progression may be so important.

I've believed that is a factor as well. Plus the toll long term chemotherapy in the original placebos before they progress takes on their immune system without DCVax-L there to help stimulate it and/or minimize the chemotherapy immune suppression effects.

(If there was a more potent version of DCVax-L created midstream, the more potent version might be able to help original placebos more. les is saying, apparently, off the record there was no midstream optimization in manufacturing.)

IMHO.